Drugs that contain Regorafenib

1. List of Stivarga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(7 months ago)

US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(8 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors
Jun, 2030

(7 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 27, 2024

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor


How can I launch a generic of STIVARGA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in